Filipino-owned medical software eyes early cancer detection
GLORI and DAWN are liquid -biopsy diagnostic tests that differentiate between malignant and benign female pelvic tumors
A Filipino-owned, first-of-its-kind, and AI-powered technology healthcare facility is gearing up to offer its technology for the early detection of cancer, as the disease remains one of the leading causes of death in the Philippines.
On Friday, InterVenn Biosciences Philippines co-founder and CEO Aldo Carrascoso told reporters that their company had made significant progress in early cancer during the launch of their state-of-the-art facility in Ortigas Center, Pasig City, attributing it "to the brilliant and dedicated Filipino engineers that InterVenn has on board."
"They help build and maintain the front end, back end, and cloud infrastructure of our next-generation liquid biopsy, as we all work together to reach a world where no one should ever be blindsided by disease," Carrascoso said when discussing how their products GLORI and DAWN came to be.
GLORI and DAWN are liquid-biopsy diagnostic tests that differentiate between malignant and benign female pelvic tumors.
According to the Department of Health, cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012, based on a study by the World Health Organization.
Also, the said disease is the third leading cause of morbidity and mortality in the Philippines after diseases of the heart and the vascular system, quoting a report by the Philippine Health Statistics in 2009.
The new site at the Podium West Tower will expand the local team's roster of developers and engineers that form the backbone running the proprietary AI technology used in the company's research. Currently, over 100 Filipinos work on the software engineering stream of InterVenn, with plans to recruit more local talent as they further expand their business in the region.
Proudly Pinoy made
InterVenn's new site, located at the Podium West Tower, will expand the local team's roster of developers and engineers that form the backbone running the proprietary AI technology used in the company's research.
Currently, over 100 Filipinos work on the software engineering stream of InterVenn, with plans to recruit more local talent as they further expand their business in the region.
"One hundred percent of our software is proudly Philippine-made. We started this venture with the goal of not just having the means of finding a cure and early detection for cancer, but to also showcase to everyone that we Filipinos can achieve this on a global scale," said InterVenn Philippines General Manager Axel Kornerup, who also proudly shared that InterVenn has been collaborating with local oncologists in running the VOCAL (InterVenn Ovarian Cancer Liquid Biopsy) testing program.
The company, armed with its new facilities and cadre of researchers, has been aggressive in its recruitment and expansion to support the development and commercialization of DAWN a blood-based test using a simple blood raw, which they unveiled last month in the health industry's largest conference for oncology ASCO 2022.